Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

Arendrup, Maiken Cavling; Chowdhary, Anuradha; Jørgensen, Karin Meinike; Meletiadis, Joseph

doi:10.1128/aac.00656-20

Cited by 49Antifungal resistance and susceptibilityFungal Plant Pathogen ControlYeasts and Rust Fungi Studies

Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

Open access

Arendrup, Maiken Cavling, Chowdhary, Anuradha, Jørgensen, Karin Meinike, Meletiadis, Joseph·2020·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.00656-20PMC PMC7508601

Open this paper in CoChat — free account

Abstract

Fosmanogepix is a novel prodrug in a new class of antifungal agents. Manogepix is the active moiety. We evaluated the CLSI and EUCAST MICs of manogepix and eight comparators against Candida auris . CLSI M27-A3 susceptibility testing of manogepix was performed for 122 C. auris isolates and compared to CLSI and EUCAST MICs for manogepix and eight comparators. Differences and agreement were calculated for each compound. Wild-type upper limits (WT-ULs; the upper MIC where the wild-type distribution ends) for manogepix and correlations with other drugs’ MICs were determined.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.00656-20

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The finding that MGX was the most active compound tested against all C. auris study isolates is consistent with previous in vitro studies showing MGX to be the most potent antifungal tested against C. auris isolates.
“This is consistent with previous in vitro studies showing MGX to be the most potent antifungal tested against C. auris isolates (21, 22).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [22]
When in vitro activity of MGX was evaluated against eight comparator agents against 122 wild type and non-wild type C. auris isolates, MGX had the most potent antifungal activity against all C. auris strains.
“When in vitro activity of MGX was evaluated against eight comparator agents against 122 wild type and non-wild type C. auris isolates, similar findings were reported, with MGX having the most potent antifungal activity against all C. auris strains (22).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [22]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · see citing works
Self-citation
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values
Turnidge, J. D., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 399 · see citing works
Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values
Arendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270 · see citing works
Self-citation
Candida auris–Associated Candidemia, South Africa
Magobo, R. E., Corcoran, C., Seetharam, S., & Govender, N. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.131765 · Cited by 259 · see citing works
Limited ERG11 Mutations Identified in Isolates of Candida auris Directly Contribute to Reduced Azole Susceptibility
Healey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrío, I., Chowdhary, A., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01427-18 · Cited by 165 · see citing works
Self-citation
Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · see citing works
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139 · see citing works
GWT1 Gene Is Required for Inositol Acylation of Glycosylphosphatidylinositol Anchors in Yeast
Umemura, M., Okamoto, M., Nakayama, K.-I., Sagane, K., Tsukahara, K., Hata, K., & Jigami, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301044200 · Cited by 127 · see citing works
Gene Duplication Associated with Increased Fluconazole Tolerance in Candida auris cells of Advanced Generational Age
Bhattacharya, S., Holowka, T., Orner, E. P., & Fries, B. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-41513-6 · Cited by 104 · see citing works
Development of Candida auris Short Tandem Repeat Typing and Its Application to a Global Collection of Isolates
de Groot, T., Puts, Y., Berrío, I., Chowdhary, A., & Meis, J. F. G. M. (2020) · mBio · doi:10.1128/mbio.02971-19 · Cited by 88 · see citing works
Self-citation
Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 81 · see citing works
In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80 · see citing works
Efficacy of delayed therapy with Fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis
Wiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71 · see citing works
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68 · see citing works
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
Kapoor, M., Moloney, M. K., Soltow, Q. A., Pillar, C. M., & Shaw, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-19 · Cited by 59 · see citing works
Activity of novel antifungal compound APX001A against a large collection of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky302 · Cited by 57 · see citing works
APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method
Arendrup, M. C., Chowdhary, A., Astvad, K. M. T., & Jørgensen, K. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-18 · Cited by 54 · see citing works
Self-citation
Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods
Pfaller, M. A., Watanabe, N., Castanheira, M., Messer, S. A., & Jones, R. N. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr342 · Cited by 50 · see citing works
Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
Liston, S. D., Whitesell, L. J., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00261-20 · Cited by 40 · see citing works
In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination
Jørgensen, K. M., Astvad, K. M. T., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00730-20 · Cited by 33 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works
Worsening Spread of Candida auris in the United States, 2019 to 2021
Lyman, M., Forsberg, K., Sexton, D. J., Chow, N. A., Lockhart, S. R., Jackson, B. R., & Chiller, T. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3469 · Cited by 287 · see citing works
Candidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260 · see citing works
Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229 · see citing works
Invasive candidiasis: current clinical challenges and unmet needs in adult populations
Soriano, À., Honoré, P. M., Puerta‐Alcalde, P., García‐Vidal, C., Pagotto, A., Gonçalves, D. C., & Verweij, P. E. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad139 · Cited by 201 · see citing works
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
Self-citation
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92 · see citing works
Development and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85 · see citing works
Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1070 · Cited by 79 · see citing works
Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents
Wiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 68 · see citing works
Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris
Billamboz, M., Fatima, Z., Hameed, S., & Jawhara, S. (2021) · Microorganisms · doi:10.3390/microorganisms9030634 · Cited by 53 · see citing works
Antifungal Pipeline
McCarty, T. P., & Pappas, P. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732223 · Cited by 47 · see citing works
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action
Hoenigl, M., Sprute, R., Arastehfar, A. A., Perfect, J. R., Lass‐Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al‐Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 46 · see citing works
Self-citation
Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives
Smith, D. J., Gold, J. A. W., Benedict, K., Wu, K., Lyman, M., Jordan, A., Medina, N., Lockhart, S. R., Sexton, D. J., Chow, N. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9080820 · Cited by 39 · see citing works
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective
Ordaya, E. E., Clement, J., & Vergidis, P. I. (2023) · Mycopathologia · doi:10.1007/s11046-023-00759-5 · Cited by 37 · see citing works
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician
Lamoth, F. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s375625 · Cited by 37 · see citing works
How urgent is the need for new antifungals?
Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36 · see citing works
In Vitro Antifungal Activity of Manogepix and Other Antifungal Agents against South African Candida auris Isolates from Bloodstream Infections
Maphanga, T. G., Mpembe, R. S., Naicker, S. D., Govender, N. P., & GERMS-SA, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01717-21 · Cited by 35 · see citing works
Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)
Pfaller, M. A., Huband, M. D., Rhomberg, P. R., Bien, P. A., & Castanheira, M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-22 · Cited by 34 · see citing works
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works
Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro
John, L. L. H., Thomson, D. D., Bicanic, T. A., Hoenigl, M., Brown, A. J. P., Harrison, T. S., & Bignell, E. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-22 · Cited by 33 · see citing works
Uniqueness of Candida auris cell wall in morphogenesis, virulence, resistance, and immune evasion
Dakalbab, S., Hamdy, R., Holigová, P., Abuzaid, E. J., Abu-Qiyas, A., Lashine, Y., Mohammad, M. G., & Soliman, S. S. M. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127797 · Cited by 27 · see citing works
Recent advances and future perspectives in the pharmacological treatment ofCandida aurisinfections
Giacobbe, D. R., Magnasco, L., Sepulcri, C., Mikulska, M., Koehler, P. A., Cornely, O. A., & Bassetti, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949285 · Cited by 27 · see citing works
In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022)
Pfaller, M. A., Huband, M. D., Bien, P. A., Carvalhaes, C. G., Klauer, A. L., & Castanheira, M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01132-23 · Cited by 26 · see citing works
Small molecules for combating multidrug-resistant superbug Candida auris infections
Tu, J., Liu, N., Huang, Y., Yang, W., & Sheng, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.001 · Cited by 26 · see citing works
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Treviño‐Rangel, R. D. J., González, G. M., Montoya, A. M., Rojas, O. C., Elizondo-Zertuche, M., & Álvarez‐Villalobos, N. A. (2022) · Journal of Fungi · doi:10.3390/jof8111144 · Cited by 25 · see citing works
Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics of Candida auris, with a Focus on Children
Ashkenazi‐Hoffnung, L., & Danziger, C. R. (2023) · Journal of Fungi · doi:10.3390/jof9020176 · Cited by 24 · see citing works
Invasive Candidiasis
Schroeder, J. A., Wilson, C. M., & Pappas, P. G. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.11.007 · Cited by 24 · see citing works
Candida auris in Austria—What Is New and What Is Different
Spettel, K., Kriz, R., Wu, C. C., Achter, L., Schmid, S., Galazka, S., Selitsch, B., Camp, I., Makristathis, A., Lagler, H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020129 · Cited by 18 · see citing works
A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin
Espinel‐Ingroff, A., & Wiederhold, N. P. (2024) · Journal of Fungi · doi:10.3390/jof10050362 · Cited by 18 · see citing works
Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods
Ceballos-Garzón, A., Holzapfel, M., Welsch, J., & Mercer, D. K. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf040 · Cited by 15 · see citing works
Current scenario of the search for new antifungal agents to treat Candida auris infections: An integrative review
de Moraes, D. C. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101232 · Cited by 14 · see citing works
TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression
Hirayama, T., Miyazaki, T., Tanaka, R., Kitahori, N., Yoshida, M., Takeda, K., Ide, S., Iwanaga, N., Tashiro, M., Takazono, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01508-24 · Cited by 12 · see citing works
Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives
Fernandes, L., Ribeiro, R., Henriques, M., & Rodrigues, M. E. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04497-2 · Cited by 14 · see citing works
Candida auris in skilled nursing facilities
Yune, P. S., Coe, J., Rao, M., & Lin, M. Y. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231189958 · Cited by 13 · see citing works
Deciphering the multidrug resistance paradigm in Candida auris
Santana, D. J., Cauldron, N. C., Rogers, P. D., & Cuomo, C. A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01062-24 · Cited by 7 · see citing works
The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo
Konings, M., Eadie, K., Strepis, N., Nyuykonge, B., Fahal, A. H., Verbon, A., & van de Sande, W. W. J. (2023) · Medical Mycology · doi:10.1093/mmy/myad118 · Cited by 7 · see citing works
Exploring therapeutic strategies for candidiasis: From current treatments to future perspectives
Kantroo, H. A., Mubarak, M. M., & Ahmad, Z. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108797 · Cited by 6 · see citing works
Spectrum and management of rare Candida /yeast infections in Kuwait in the Middle East
Ahmad, S., Asadzadeh, M., Al‐Sweih, N., & Khan, Z. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241263733 · Cited by 5 · see citing works
Candidozyma auris Alert in South America: An Epidemiological and Therapeutic Update
Marena, G. D., Nosanchuk, J. D., & Taborda, C. P. (2025) · Current Tropical Medicine Reports · doi:10.1007/s40475-024-00338-8 · Cited by 4 · see citing works
New Perspectives on Antimicrobial Agents: Fosmanogepix
Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 3 · see citing works
Manogepix demonstrates potent in vitro activity against Aspergillus, Coccidioides , Scopulariopsis/Microascus, Rasamsonia , and Purpureocillium species, including strains with in vitro resistance to other antifungals
Wiederhold, N. P., Patterson, H. P., Sanders, C. J., & Cañete-Gibas, C. F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-26 · Cited by 2 · see citing works
Prospective Medicines against the Widespread, Emergent, and Multidrugresistant Opportunistic Fungal Pathogen Candida auris: A Breath of Hope
Ramos, L. S., Silva, L. N., de Mello, T. P., Frota, H. F., Branquinha, M. H., & dos Santos, A. L. S. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220520153748 · Cited by 2 · see citing works
Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options
Negi, P., Verma, N., Rishi, P., Multani, K., Sharma, M., Kumari, S., & Raj, K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04864-z · Cited by 1 · see citing works
Candida auris in the neonatal intensive care unit
L’Etoile, N., & Murray, T. S. (2026) · Seminars in Perinatology · doi:10.1016/j.semperi.2026.152249 · Cited by 1 · see citing works
Wild-type MIC distributions and epidemiological cut-off values for ibrexafungerp, manogepix, and rezafungin against WHO fungal priority pathogens
Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1 · see citing works
Susceptibility Test Methods: Yeasts and Filamentous Fungi
Johnson, E. M., & Arendrup, M. C. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0135 · Cited by 1 · see citing works
Self-citation
Susceptibility Test Methods: Yeasts and Filamentous Fungi
Johnson, E. M., & Arendrup, M. C. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0135 · Cited by 1 · see citing works
Self-citation
Clinical Efficacy and Safety of Fosmanogepix in Patients with Invasive and Refractory Fungal Infections: A Systematic Review
Bratosin, F., Bogdan, I. G., & Pescariu, S. A. (2026) · Journal of Fungi · doi:10.3390/jof12100733

In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak
Zhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-20 · Cited by 50 · see citing works
Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 63 · see citing works
In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination
Jørgensen, K. M., Astvad, K. M. T., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00730-20 · Cited by 33 · see citing works
Self-citation
1275. Evaluation of in vitro activity of manogepix against multidrug-resistant and pan-resistant Candida auris from the New York Outbreak
Zhu, Y. C., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V. P. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.1459
Activity of manogepix and comparator antifungal agents against uncommon filamentous fungal isolates collected in a global surveillance program
Winkler, M., Klauer, A. L., Edeker, S., Fedler, K. A., Rhomberg, P. R., & Castanheira, M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02559-26

Authors: Arendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J.
Affiliations: Statens Serum Institut (DK)
University of Delhi (IN)
National and Kapodistrian University of Athens (GR)
ORCID: Arendrup, Maiken Cavling
Chowdhary, Anuradha
Jørgensen, Karin Meinike
Meletiadis, Joseph
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2020-09-21
Volume: 64
Issue: 10
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.00656-20
PMC: PMC7508601
OpenAlex: W3040732415
Cited by: 49
References: 20
Citations by year: 2026: 7 · 2025: 3 · 2024: 7 · 2023: 13 · 2022: 10 · 2021: 8 · 2020: 1
FWCI: 1.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
PubMed Central (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Funders: Pfizer
Gilead Sciences
Cidara Therapeutics
Amplyx
Astellas Pharma
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
Keywords: manogepix, fosmanogepix, Candida auris, antifungal susceptibility, minimum inhibitory concentration, EUCAST, CLSI, prodrugs, antifungal agents
MeSH terms: Aminopyridines, Antifungal Agents, Candida, Isoxazoles, Microbial Sensitivity Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks